Diverse Array of Therapies

IMG-1 normalizes glucose, cholesterol, and blood pressure addressing complications found in pre-diabetes and T2D.  Additional therapeutic opportunities include anti-viral, skin cancer and lung healing.  Imagine Pharma’s efforts currently focus on the topical treatment for wound healing.

ProgramDiscoveryPre-ClinicalPhase 1
Therapeutics Top-1 Skin Graft (Donor)
Discovery
Pre-Clinical
Phase 1
Top-2 Diabetic Wound
Discovery
Pre-Clinical
Phase 1
Top-3 Burns (2nd Degree)
Discovery
Pre-Clinical
Phase 1
Key
2021-2022
2022-2023

Diabetic Wound Healing Acceleration (Top-2)

10.0mm x 10.0mm wound in a healing-impaired db/db diabetic mouse Receiving 0.5% HPMC

10.0mm x 10.0mm wound in a healing-impaired db/db diabetic mouse Receiving 4µg/mL IMG-1 in 0.5% HPMC

RESEARCH & DEVELOPMENT ENGINE

Powering New Discovery

The foundation of the three platforms forms the basis of a multi-year scientific inquiry which will lead to many discoveries and potential therapies to increase the number of patients that can benefit from our transformative first-in-class treatments. With research programs targeting areas where there are currently no treatments and current approaches are not cost effective or have failed, Imagine is pushing the boundaries of what is possible.

We are actively seeking partnerships for the development of complementary therapeutic approaches to explore a broader set of indications and reach more patients.

R & D EngineDiscoveryPre-ClinicalPhase 1
2nd Generation Oral Delivery System
Discovery
Pre-Clinical
Phase 1
Additional Oral Biologics
Discovery
Pre-Clinical
Phase 1
Comprehensive Lung Healing Initiative
Discovery
Pre-Clinical
Phase 1
Comprehensive Bowel Initiative
Discovery
Pre-Clinical
Phase 1
Personalized Blood
Vessel
Discovery
Pre-Clinical
Phase 1